Cancer incidence and mortality and risk factors in member countries of the "Belt and Road" initiative

Baohua Wang¹, Fengdie He¹, Yanan Hu², Qiutong Wang¹, Dan Wang², Yuting Sha¹ and Jing Wu¹*

Abstract

Background: At present, "Belt and Road" ("B&R") member states (accounting for about 61.78% of the world's population) face different types of cancer threats to varying degrees. We analyzed the incidence and mortality and risk factors of cancer in the member countries of the "B&R" to explore the basis of health and medical cooperation between countries and provide a foundation for formulating cancer prevention and control policies for building a healthy "B&R".

Methods: Data were derived from the Global Cancer Observatory and Cancer Country Profiles in 2020. Incidence and mortality were age-standardized rates (ASRs). Population attributable fractions (PAFs) was applied to measure risk factors of cancers in the "B&R" countries. The mortality to incidence ratio (MIR) was calculated by dividing the mortality rate by the incidence rate.

Results: A total of 26 cancers were included in the study. Lung, breast, colorectal, stomach, liver, prostate, cervical, esophageal, thyroid, and uterine cancers were the most common and highest in age-standardized mortality in the "B&R" countries. For men, Hungary had the highest cancer age-standardized incidence and mortality (ASR, 289.3 per 100,000 and ASR, 235.7 per 100,000, respectively), followed by Latvia (ASR, 288.6 per 100,000 and ASR, 196.5 per 100,000, respectively). In females, the highest incidence rates were estimated in Greece (ASR, 238.7 per 100,000), and the highest mortality rate was Brunei (ASR, 192.3 per 100,000). All countries were in the middle or high HDI range, with about half (46.88%) of countries achieving high HDI, mostly in Central and Eastern Europe (13 countries) and West Asia (10 countries). The United Arab Emirates had the highest MIR in male and female (1.59 vs 2.19). Tobacco products, infectious factors, and ultraviolet rays were the three main cancer risk factors in the "B&R" countries.

Conclusion: The overall burden of cancer in the countries along the "B&R" remains substantial, while the corresponding cancer prevention and control policies need to be improved. Strengthening health cooperation among member countries will contribute to a joint response to the risks and challenges posed by cancer.

Keywords: "B&R", Cancer incidence, Cancer mortality, Risk factors, Cancer prevention strategies

Introduction

More than 2,000 years ago, people on the Eurasian continent explored many trade and cultural exchange routes that connected the major civilizations of Asia, Europe, and Africa, and later generations collectively referred to these routes as the "Silk Road" [1]. During Chinese President Xi Jinping's visits to Central and Southeast Asian
countries in September and October 2013, he proposed jointly building the "Silk Road Economic Belt" and the "21st Century Maritime Silk Road." The "B&R" achieves the common development and common prosperity of all member states by building a community of interest, destiny, and responsibility in all aspects of political mutual trust, economic integration, and cultural inclusiveness.

In recent years, with the development of society and the economy, the disease burden in low–human development index (HDI) and medium-HDI countries has shifted from being dominated by communicable, maternal, neonatal, and nutritional diseases (CMNNDS) to being dominated by non-communicable diseases (NCDs) and injuries [2]. With the improvement of clinical diagnosis and treatment, cancer is among the ranks of chronic non-infectious diseases and is one of the main components of the NCDs burden. Cancer is the second leading cause of deaths after cardiovascular disease in the world, accounting for about 10.1 million deaths (17.83% of total deaths) in 2019 [3]. As health is a core issue of human development, China's "B&R" initiative provides a great opportunity for cooperation and collective action among multiple countries. In 2016, working together to build a healthy Silk Road, taking health as one of the important contents of the “B&R” construction was proposed by Xi Jinping. The development of health undertakings is directly related to the national and regional SDG and was the driving force for the construction of the "B&R" [4]. At present, member states face different types of cancers threats to varying degrees. Understanding the status quo and risk factors of cancer in the "B&R" member states is an important foundation for health cooperation between countries. Therefore, based on global data of cancer and cancer country profiles released by the World Health Organization in 2020, we analyzed the incidence, mortality, and risk factors of cancer in the member countries of the "B&R" to provide a basis for formulating cancer prevention and control policies for building a healthy "B&R."

**Index definition**

In this study, we used incidence, mortality, and age-standardized rates (ASRs) to analyze and compare cancer incidence and death in "B&R" countries. Incidence, generated by population-based cancer registries (PBCRs), is the number of new cases occurring in a specified period and geographic region, and conveyed either as an absolute number of cases per annum or as a rate per 100,000 people per year. Mortality, similarly, is used to measure the number of deaths per unit of time (overall or attributable to specific factors) in a population of a given size. It is usually expressed in units per 100,000 people per year. ASRs per 100,000 people-years are corrected by the direct method and the world standard population to allow for differences in the age structure of a population. The methods used to estimate the global incidence and mortality in 2020 (for all ages) can be found in other literature [8, 9]. We calculated the mortality-to-incidence ratio (MIR) by dividing the mortality rate by the incidence rate [10, 11]. The population attributable fractions (PAFs) refer to the proportion of the incidence or death of a disease attributable to a certain exposure factor in the total

**Materials and methods**

**Data source**

We used data from the Global Cancer Observatory (gco.iarc.fr) [5] and Cancer Country Profiles (https://www.who.int/countries) [6] in 2020. Global Cancer Observatory, an online data set that provides a comprehensive assessment of the Global Cancer burden in 2020 based on GLOBCAN estimates of incidence, mortality for 36 cancer types, grouped by sex and age, in 185 countries or territories in 2020. The methods used in compiling the estimates in GLOBCAN were country-specific, and the quality of the national estimates depended on the coverage, accuracy, and timeliness of the recorded incidence and mortality data in each country. More details are described in other literature [7].

"B&R" initiative refers to the cooperative organization of politics, economics, culture, and other related fields, and includes 66 member countries. Apart from Cyprus, the Czech Republic, Greece, Hungary, Israel, and Singapore, the remaining 60 countries are all developing countries: (1) East Asia: China, Mongolia; (2) The association of southeast Asian nations (ASEAN): Singapore, Malaysia, Indonesia, Myanmar, Thailand, Laos, Cambodia, Vietnam, Brunei, and the Philippines; (3) West Asia: Iran, Iraq, Turkey, Syria, Jordan, Lebanon, Israel, Palestine, Saudi Arabia, Yemen, Oman, United Arab Emirates, Qatar, Kuwait, Bahrain, Greece, Cyprus, and Egypt's Sinai Peninsula; (4) South Asia: India, Pakistan, Bangladesh, Afghanistan, Sri Lanka, the Maldives, Nepal, and Bhutan; (5) Central Asia: Kazakhstan, Uzbekistan, Turkmenistan, Tajikistan, and Kyrgyzstan; (6) The Commonwealth of Independent States (CIS): Russia, Ukraine, Belarus, Georgia, Azerbaijan, Armenia, and the Republic of Moldova; (7) Central and Eastern Europe (CEE): Poland, Lithuania, Estonia, Latvia, Czech Republic, Slovakia, Hungary, Slovenia, Croatia, Bosnia and Herzegovina, Montenegro, Serbia, Albania, Romania, Bulgaria, and Macedonia. The division of the “B&R” countries is based on the World Bank’s division of global regions and international political and economic organizations. There is a lack of cancer-related data in Palestine and Yemen in this database. Therefore, we collected and analyzed cancer data in the other 64 member states.
incidence or death of a disease in the population, that is, the proportion of the incidence or death of related diseases that can be reduced in the population after the elimination of exposure factors. The specific calculation method is detailed in other literature [12].

Data analysis
We conducted a descriptive analysis and comparison of the incidence and deaths due to cancers in the “B&R” countries, as well as a visual presentation. Microsoft Excel 2019 was used for data visualization.

Results
Age-standardized incidence and mortality of cancers in global and geographical distribution of the “B&R” countries
A total of 26 cancers were included in the study. Breast, lung, colorectum, prostate, stomach, liver, cervix uteri, esophagus, thyroid, and bladder cancer ranked amongst the top 10 new cancer in 2020, and lung, colorectum, liver, stomach, breast, esophagus, pancreas, prostate, cervix uteri, and leukaemia cancer ranked among the top 10 cancers in terms of deaths, with a total of 12,176,526 new cases and 7,054,094 deaths worldwide, respectively (Table 1). Among the “B&R” member countries, the top 10 cancers with the highest incidence rate were lung, breast, colorectum, stomach, liver, esophagus, prostate, cervix uteri, thyroid, and corpus uteri cancers. The top 10 cancers with the highest mortality rate were lung, liver, stomach, colorectum, esophagus, breast, cervix uteri, prostate, pancreas, and ovary cancers. The member countries of the “B&R” had lower cancer incidence and higher cancer mortality compared to the world (Fig. 1A). The cancer with the highest incidence and mortality ASRs was lung cancer in the world and the “B&R” member countries in male, while breast cancer in female (Fig. 1B, C).

Distribution of cancer in each member country of the “B&R”
Table 2 shows the total number of the top 10 newly diagnosed cancer cases and deaths, as well as the incidence and mortality ASRs and MIR separately in each member country of the “B&R” in males and females. All countries were in the middle or high HDI range, with about half (46.88%) of countries achieving high HDI, mostly in Central and Eastern Europe (13 countries) and West Asia (10 countries). Among all the “B&R” member countries, the country with the highest incidence and mortality of cancers among males was Hungary (ASR, 289.3 per 100,000 and ASR, 235.7 per 100,000, respectively), followed by Latvia (ASR, 288.6 per 100,000 and ASR, 196.5 per 100,000, respectively), and the United Arab Emirates and Saudi Arabia, which enjoyed the lowest rates of incidence and mortality, respectively (ASR, 34.3 per 100,000 and ASR, 36.1 per 100,000, respectively). In females, the highest incidence rates were estimated in Greece (ASR, 238.7 per 100,000), followed by Mongolia, Turkey, Cyprus, Singapore, and Brunei. The country with the highest mortality rate was Brunei (ASR, 192.3 per 100,000), followed by Israel, Singapore, Cyprus, Greece, and Mongolia. Among the “B&R” member countries, the country with the highest cancer incidence among men was the United Arab Emirates (1.59), followed by Kuwait (1.17), and Turkey had the lowest MIR (0.45). Among women, the United Arab Emirates also had the highest MIR (2.19), followed by Afghanistan (1.64), and Belarus (0.37). See Table 2 for more details.

Among the top 10 cancers in East Asian countries, the total incidence and mortality of cancer in Mongolia were ASR, 158.0 per 100,000 and ASR, 128.8 per 100,000, respectively, and both were larger in females than in males. Liver cancer had the highest cancer incidence and mortality. The total cancer incidence and mortality in China were 146.3 per 100,000 and 84.4 per 100,000, respectively, and lung cancer and breast cancer had the highest cancer incidence and mortality, respectively (supplementary Fig. S1).

Among ASEAN countries, Singapore had the highest cancer incidence (ASR, 149.4 per 100,000) and Vietnam had the highest cancer mortality (ASR, 58.9 per 100,000). The countries with the highest overall cancer incidence and mortality among males were Singapore and Laos (ASR, 132.9 per 100,000 and ASR, 80.4 per 100,000, respectively), while for females, the country was Brunei, with an overall cancer incidence and mortality of ASR, 137.4 per 100,000 and ASR, 52.9 per 100,000, respectively. Cancers of the colorectum, lung, prostate, and liver in men, and cancers of the breast, lung, colorectum, and cervix uteri in female, continue to be the most common fatal cancers (supplementary Fig. S2).

Among the member countries in West Asia, the highest cancer incidence rate was observed in Cyprus, Greece, and Israel, with a high cancer incidence of cancers of the breast, prostate, lung, and colorectum, while Turkey, Egypt, and Syria had the highest cancer mortality, and deaths associated with cancers of the lung, breast, liver, prostate, colorectum, and bladder deaths were the most numerous. Cancer incidence and mortality rates were highest among males in Greece (ASR, 238.7 per 100,000) and Turkey (ASR, 143.7 per 100,000), with lung, prostate, bladder, and colorectal cancer being the main causes. Israel, Greece, and Cyprus had the highest cancer incidence rates of the breast, thyroid, corpus uteri, and colorectum in females. The top three countries with the highest cancer mortality were Cyprus, Egypt, and Iraq, where principal deaths of cancer were cancers of the
| Cancer Site       | World New cases | East Asia New cases | Asean New cases | West Asia New cases | South Asia New cases | Central Asia New cases | CIS New cases | CEE New cases |
|------------------|-----------------|---------------------|----------------|---------------------|----------------------|------------------------|---------------|---------------|
|                  | Deaths          | New cases           | Deaths         | New cases           | Deaths               | New cases              | Deaths        | Deaths        |
| Breast           | 2,096,349       | 69,8906             | 416,559        | 117,236            | 1,588,200            | 586,22                 | 991,16        | 33,153        |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Lung             | 1,926,151       | 88,710              | 75,119         | 1,232,211           | 1,094,422            | 68,712                 | 9,973,34      | 91,007        |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Colorectum       | 1,631,590       | 93,173              | 555,637        | 286,262             | 1,069,199            | 570,22                 | 63,198        | 31,821        |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Prostate         | 1,642,519       | 375,304             | 115,462        | 511,11              | 430,438              | 195,29                 | 487,16        | 16,279        |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Stomach          | 1,619,901       | 78,793              | 479,638        | 374,422             | 3,301,12             | 2,265,96                | 343,582       | 209,64        |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Liver            | 1,693,768       | 83,149              | 12,471         | 3,392,12            | 992,11               | 595,17                 | 379,352       | 375,98        |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Cervix uteri     | 6,641,127       | 34,183               | 110,075        | 7,942,49            | 682,49               | 383,19                 | 1,487,69      | 69,41         |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Oesophagus       | 6,041,000       | 5,440,76             | 3,348,20       | 1,031,08            | 1,027,8              | 9,704                  | 9,043,86      | 9,0947        |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Thyroid          | 5,862,028       | 4,364,96             | 2,078,198      | 9,261               | 2,847,51              | 2,397,6                | 2,471,99      | 2,031         |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Bladder          | 5,732,784       | 2,125,36             | 526,24         | 1,081,09            | 538,3                 | 367,45                 | 46,32         | 2,715         |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Pancreas         | -               | 70,509               | 67,994         | 24,49               | 2,865,794             | 1,702,07              | 1,636,74      | 18,8          |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Melanoma of skin| -               | -                    | -              | -                   | -                    | 1,167                  | 194           | -             |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Corpus uteri     | -               | 81,964               | 16,007         | 2,122,78            | 7,238                | 15,203                 | 4,097,23      | 23,16         |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Ovary            | -               | 55,423               | 37,658         | 2,973,74            | 1,906,73             | 8,373,3                 | 5,540,79      | 1,237,59      |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Non-Hodgkin lymphoma | - | 50,155             | 27,941         | 35,466              | 2,021,72             | 1,476,52              | 792,99        | 462,22        |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Leukemia         | -               | -                    | -              | -                   | -                    | 34,992                 | 6,457,39      | 8,48,75       |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Kidney           | -               | 118                  | 42             | 27,55               | 1,338                | 342,34                 | 1,440,98      | 100,94        |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Brain, central nervous system | - | 34                  | 30             | 514                 | 446                 | 13,750                | 1,606,30      | 1,462,20      |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Hypopharynx      | -               | -                    | -              | -                   | -                    | 30,30                  | 176,0         | -             |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Larynx           | -               | -                    | -              | -                   | -                    | 1,223                 | 744,85        | 39,6         |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Lip, oral cavity | -               | -                    | -              | -                   | -                    | 8,24                 | 6,478,90      | 171,170      |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Nasopharynx      | -               | -                    | -              | -                   | -                    | 27,190                | 18,352        | -             |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Hodgkin lymphoma | -               | -                    | -              | -                   | -                    | 123                  | 311,314       | -             |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Gallbladder      | -               | -                    | -              | -                   | -                    | 635,3                 | 49,78         | -             |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Oropharynx       | -               | -                    | -              | -                   | -                    | 3,266                 | 2,007         | -             |
|                  |                 |                     |                |                     |                      |                        |               |               |
| Total            | 12,176,526      | 6,532,679            | 3,775,772      | 2,489,033           | 8,488,64             | 5,238,55              | 5,442,86      | 3,108,45      |

Table 1: New Cases and Deaths of main cancers for global and geographical location of the “B&R” countries Combined in 2020.
breast, lung, colorectum, ovary, and cervix uteri; leukemia, brain, and central nervous system were all in the top five cancer death types in Iraq. See supplementary Fig. S3 for more details.

Large distribution differences existed in the incidence and mortality of cancers in South Asian member countries, with the total number of newly diagnosed cancer cases in Bhutan being much higher than that in other countries (ASR, 176.2 per 100,000). Bangladesh had some of the highest cancer incidence rates in males (ASR, 153.6 per 100,000), such as lung, prostate, and colorectal cancers. There was a high incidence of breast cancer, colorectal cancer, non-Hodgkin lymphoma, and esophageal cancers in females in Afghanistan (ASR, 119.9 per 100,000) and the Maldives (ASR, 115.4 per 100,000). On the contrary, deaths were more evenly distributed across countries, with the most deaths being from lung cancer and digestive system cancer in males and breast cancer and lung cancer in females. See supplementary Fig. S4 for more details.

Lung, prostate, colorectal, and stomach cancers in males in Kazakhstan and Uzbekistan had a high incidence among the Central Asian countries, while a small difference in the incidence and mortality of cancers was observed in females; cancers of the breast, cervix uteri, colorectum, corpus uteri, and stomach were the main ones (supplementary Fig. S5). Among the member states of the CIS countries, the highest cancer incidence among both sexes was observed in Belarus and Russia, with the top five most common cancers being those of the prostate, breast, colorectum, lung, and corpus uteri. Similarly, the highest cancer mortality occurred in Armenia and the Republic of Moldova, primarily in association with cancers of the lung, breast, prostate, colorectum, and stomach (supplementary Fig. S6).

The incidence of cancer in the member states of Central and Eastern Europe was the highest among all the member states of the "B&R"; the combined cancer incidence was over ASR 200.0 per 100,000. The cancer mortality rate was relatively low, with an ASR of 100.0 per 100,000 on average. Hungary had the most serious cancer incidence and death rates, with a total incidence rate of ASR 321.1 per 100,000 and a total mortality rate of ASR 125.2 per 100,000. Prostate and breast cancers were the two most commonly diagnosed cancer types, and lung, colorectum, breast, and prostate cancers were the leading causes of cancer death (supplementary Fig. S7).

**Distribution of major cancers in the "B&R" member states**

The main cancer burdens in the member states of the "B&R" were lung, breast, colorectal, stomach, liver, prostate, and cervical cancer. In terms of the incidence and mortality of lung cancer, CEE member countries carried the heaviest one, and the burden of males was approximately four- to fivefold higher than that of females (Fig. 2A). The incidence of breast cancer showed a greatly different, ranging from ASR 25.46 per 100,000 to ASR 56.96 per 100,000. However, this was less marked in terms of mortality (Fig. 2B). The burden of colorectal cancer in males was twice that in females, and the burden of incidence was twice that of mortality. The heaviest burden of incidence and mortality of colorectal cancer was observed in CEE member states, followed by the CIS and ASEAN countries (Fig. 2C). East Asian member states had the largest burden of incidence and mortality of stomach cancer, at two to four times and one to five times the rates of other member states, respectively (Fig. 2D). The same was true of liver cancer, which were three to 30 times and six to 30 times the rates that of other member states, respectively (Fig. 2E). The incidence of prostate cancer was relatively high, while the opposite was true of the mortality rate; and the incidence and mortality burden of prostate cancer in CEE member states was the heaviest, with ASR 53.81 per 100,000 and ASR 14.26 per 100,000, respectively (Fig. 2F). The incidence and mortality of cervical cancer were evenly distributed in the member states, with the exception of the lowest incidence in West Asia. The incidence and mortality in other member countries ranged from ASR 11.00 per 100,000 to ASR 17.00 per 100,000 and ASR 5.00 per 100,000 to ASR 10.00 per 100,000 (Fig. 2G).

**Three main risk factors for cancers in the "B&R" member states**

According to our statistics, tobacco products, infectious factors, and ultraviolet rays were the three main risk factors for cancers in the “B&R” member countries. Tobacco products were the biggest challenge facing all member states, causing the highest burden of cancer incidence and mortality in East Asia and CEE (Fig. 3A). The mean PAF scores of tobacco products were estimated at 30% and above in the following 10 member states: Serbia, Greece, Hungary, Bosnia and Herzegovina, Bulgaria, Croatia, Poland, Romania, Turkey, and China. PAF score above 20% was estimated in a further 27 members. Infectious factors were the most predominant risk factors for cancers in ASEAN, CEE, and East Asia, with PAFs of 151.35%, 87.13%, and 37.00%, respectively (Fig. 3B). There were five member states with more than 30% of PAFs, Vietnam, Singapore, Romania, Mongolia, and Laos, and 11 member states with more than 20%. The cancer burden caused by ultraviolet rays was mainly concentrated in the member states of CEE, CIS, Central Asia, and West Asia (Fig. 3C). Similarly, more than 50% of PAFs, dominated by CEE, were estimated in 18 member states: Estonia, Georgia, Kazakhstan, Latvia, Hungary,
Israel, Belarus, Bulgaria, Croatia, Cyprus, Czech Republic, Lithuania, Poland, Romania, Russia, Serbia, Slovenia, Ukraine. There were eight other member states with PAFs above 30%.

Discussion

In the present study, we analyzed the incidence, mortality, and risk factors of cancer in the member states of the “B&R.” The results show that the main cancer burdens in the member states of the “B&R” were lung, breast, colorectal, stomach, liver, prostate, and cervical cancer. Different member states faced different types of cancer threats to varying degrees. Furthermore, tobacco products, infectious factors, and ultraviolet rays were found to be the three main risk factors of cancer in the “B&R” countries.

Cancer poses a growing global threat to human health [13]. In 134 out of 183 countries, cancer is the first or second leading cause of premature death (i.e., 30–69 years of age), and in another 45 countries, cancer is ranked third or fourth [14]. Death rates from NCDs, particularly cancer, are declining in most high-income countries, but not in low-income countries. By 2040, cancer incidence is projected to increase by the largest percentage in countries with low and medium HDI. From 2018 to 2040, the estimated increase is 100% in the low HDI tier and 75% in the middle HDI tier, looking at population changes alone [3]. Most of countries of the “B&R” are developing countries, other than Cyprus, Czech Republic, Greece, Hungary, Israel, and Singapore. Lung cancer, breast cancer, gastrointestinal cancer, prostate cancer, cervical cancer, thyroid cancer, and uterine cancer are common challenges that the “B&R” countries must face together. Countries with low to medium HDI levels are currently ill-equipped to cope with the coming increase in the cancer burden. Thus, the health "One Belt One Road" initiative offers new solutions to the challenge of the cancer burden in –low and medium HDI countries. Strengthening regional scientific and technological cooperation through targeted, resource-sharing, effective, and cost-effective means, such as establishing combined laboratories or research centers and transferring international technology and knowledge, are necessary measures to reduce the burden of cancers [15, 16]. Furthermore, countries with high MIR often lack proper health policies or recommendations for cancer control. A multipronged approach is required to strengthen the health care infrastructure in these countries, which includes collaboration between national governments, on-the-ground primary care providers, medical subspecialists, and the wider public health community.

Cancer is a complex disease, and the incidence and death of cancer vary widely among member states. In this study, the highest lung and digestive tract cancer incidence occurred in East Asia, whereas breast cancer and lung cancer showed predominance in ASEAN, West Asia, South Asia, and Central Asia. In South Asia, lip cancer and oral cavity cancer were the leading causes of cancer deaths. South and Central Asia accounted for more than a third of the global oral cancer burden. In 2018, India had the highest burden of oral cancer, with approximately 120,000 new cases [3]. In member countries in CIS and CEE, colorectal cancer and lung cancer were the most diagnosed cancers with the highest mortality, of which the CEE countries had a high incidence of predominantly male cancers, such as bladder and...
| Region   | Country    | population | The proportion in the world population (%) | HDI* | Incidence | Mortality | MIR |
|----------|------------|------------|--------------------------------------------|------|-----------|-----------|-----|
|          |            |            |                                            |      | Males     | Males     |     |
|          |            |            |                                            |      | Females   | Females   |     |
|          |            |            |                                            |      | Males     | Females   |     |
|          |            |            |                                            |      | ASR (world) | ASR (world) |     |
|          |            |            |                                            |      | ASR (world) | ASR (world) |     |
|          |            |            |                                            |      | ASR (world) | ASR (world) |     |
| East Asia|            |            |                                            |      |            |            |     |
|          | China      | 1,402,112,000 | 18.09                                      | 0.761 | 207,1503 | 110.9 | 156,9685 | 152.5 |
|          | Mongolia   | 3,278,292   | 0.04                                       | 0.737 | 273,1 | 203.3 | 236,363 | 235.3 |
| ASEAN    | Brunei     | 437,483     | 0.01                                       | 0.838 | 369 | 105.9 | 205 | 180 |
|          | Cambodia   | 16,718,971  | 0.22                                       | 0.954 | 5,985 | 89 | 4,899 | 108 |
|          | Indonesia  | 273,523,621 | 3.53                                       | 0.718 | 127,024 | 67.8 | 85,670 | 97.1 |
|          | Laos       | 7,275,556   | 0.09                                       | 0.613 | 3,395 | 112.5 | 2,780 | 134.5 |
|          | Malaysia   | 32,365,998  | 0.42                                       | 0.81 | 17,375 | 70.3 | 11,809 | 104.2 |
|          | Myanmar    | 54,409,794  | 0.70                                       | 0.583 | 24,093 | 89.9 | 19,613 | 153.6 |
|          | Philippines| 109,581,085 | 1.41                                       | 0.718 | 51,138 | 93.4 | 36,435 | 127 |
|          | Singapore  | 5,685,807   | 0.07                                       | 0.938 | 9,670 | 110.7 | 5,818 | 186 |
|          | Thailand   | 69,799,978  | 0.90                                       | 0.777 | 70,395 | 94.1 | 52,769 | 128.7 |
|          | Vietnam    | 97,338,583  | 1.26                                       | 0.704 | 79,763 | 89.9 | 62,988 | 153.6 |
| West Asia| Bahrain    | 1,701,583   | 0.02                                       | 0.852 | 418 | 50.7 | 228 | 82.7 |
|          | Cyprus     | 1,207,361   | 0.02                                       | 0.887 | 2,217 | 95.81 | 1,128 | 216.9 |
|          | Egypt      | 102,334,403 | 1.32                                       | 0.707 | 51,272 | 103.7 | 39,199 | 130.8 |
|          | Greece     | 10,715,549  | 0.14                                       | 0.888 | 29,098 | 109.9 | 15,835 | 238.7 |
|          | Iran       | 83,992,953  | 1.08                                       | 0.793 | 51,111 | 84 | 36,096 | 120.7 |
|          | Iraq       | 40,222,503  | 0.52                                       | 0.674 | 9,721 | 67.2 | 6,856 | 91.2 |
|          | Israel     | 9,216,900   | 0.12                                       | 0.919 | 11,236 | 89.9 | 5,034 | 153.6 |
|          | Jordan     | 10,203,140  | 0.13                                       | 0.729 | 3,956 | 79.6 | 2,577 | 118.8 |
|          | Kuwait     | 4,270,563   | 0.06                                       | 0.806 | 1,304 | 45.6 | 632 | 78 |
|          | Lebanon    | 6,825,442   | 0.09                                       | 0.744 | 42,366 | 71.8 | 2,631 | 116.7 |
|          | Oman       | 5,106,622   | 0.07                                       | 0.813 | 1,486 | 89.9 | 935 | 153.6 |
|          | Qatar      | 2,881,060   | 0.04                                       | 0.848 | 632 | 50.1 | 320 | 79.6 |
|          | Saudi Arabia| 34,813,867 | 0.45                                       | 0.854 | 9,945 | 38.1 | 5,284 | 63.7 |
|          | Syria      | 17,500,657  | 0.23                                       | 0.567 | 6,653 | 76.5 | 4,681 | 107.3 |
|          | The united Arab emirates | 34,813,867 | 0.45 | 0.89 | 1,530 | 34.3 | 688 | 61.3 |
|          | Turkey     | 84,339,067  | 1.09                                       | 0.82 | 103,677 | 143.7 | 66,139 | 227.3 |

Table 2: HDI, Incidence, Mortality and MIR for "the Belt & Road" countries and Sex for the top ten cancers combined (Including Nonmelanoma Skin Cancer) in 2020.
Table 2 (continued)

| Region | Country          | Population | Male Incidence | Female Incidence | Male Mortality | Female Mortality | MIR Male | MIR Female |
|--------|------------------|------------|----------------|------------------|---------------|-----------------|----------|------------|
| South Asia | Afghanistan | 38,928,383 | 0.51 | 6.776 | 6.14 | 73.2 | 5,676 | 119.9 | 0.97 | 1.64 |
|         | Bangladesh      | 164,689,383 | 0.63 | 60.935 | 89.9 | 45.215 | 153.6 | 51,330 | 5,379 | 68.7 | 0.34 | 0.45 |
|         | Bhutan          | 77,612 | 0.65 | 4.156 | 63.2 | 6.19 | 4.61 | 140 | 59.6 | 0.38 | 0.83 |
|         | India           | 1,380,004,385 | 0.65 | 4.177 | 19.2 | 62.041 | 154.5 | 50.386 | 73.7 | 1.06 | 1.19 |
|         | Maldives        | 540,542 | 0.74 | 1.964 | 94.1 | 51.11 | 88 | 154 | 88.9 | 0.75 | 1.23 |
|         | Nepal           | 29,166,898 | 0.62 | 5.89 | 30.3 | 4.36 | 53.1 | 92 | 6.013 | 77.2 | 1.00 | 1.11 |
|         | Sri Lanka       | 2,191,000 | 0.55 | 5.079 | 48.4 | 6.367 | 67.9 | 9.725 | 37.250 | 6.23 | 0.83 |
| Central Asia | Kazakhstan | 18,754,440 | 0.82 | 5.18 | 59.9 | 8.25 | 153.6 | 7.406 | 114.4 | 0.63 | 0.74 |
|         | Kyrgyzstan      | 6,591,600 | 0.69 | 6.548 | 115.9 | 6.236 | 154.5 | 8.027 | 134.2 | 0.63 | 0.61 |
|         | Tajikistan      | 9,937,142 | 0.66 | 4.59 | 50.1 | 1.97 | 89.9 | 2.72 | 6.4 | 10.02 |
|         | Turkmenistan    | 6,031,187 | 0.71 | 1.98 | 69.2 | 2.124 | 9.2 | 1.64 | 91 | 1.06 |
|         | Uzbekistan      | 34,232,050 | 0.72 | 5.934 | 58 | 7.76 | 50.3 | 7.914 | 78.9 | 0.87 | 1.02 |
| CEE     | Armenia         | 2,963,234 | 0.77 | 3.987 | 205.9 | 2.867 | 144.7 | 3.327 | 125.7 | 0.71 | 0.51 |
|         | Azerbaijan      | 10,110,116 | 0.76 | 6.598 | 244.7 | 8.768 | 153.6 | 7.767 | 91 | 0.77 | 0.69 |
|         | Belarus         | 9,988,861 | 0.82 | 6.23 | 247.4 | 9.266 | 134.6 | 15.288 | 167.8 | 6.031 | 0.72 | 0.37 |
|         | Georgia         | 3,714,000 | 0.75 | 4.813 | 196.7 | 3.486 | 13.5 | 4.743 | 133.4 | 0.82 | 0.46 |
|         | Moldova         | 6,037,820 | 0.67 | 6.68 | 190.7 | 3.833 | 134.9 | 4.718 | 131.6 | 0.64 | 0.46 |
|         | Norway          | 4,143,040 | 0.62 | 5.658 | 210.1 | 1.992 | 124.6 | 2.255 | 152.35 | 9.84 | 0.68 |
|         | Ukraine         | 4,143,040 | 0.62 | 5.658 | 210.1 | 1.992 | 124.6 | 2.255 | 152.35 | 9.84 | 0.68 |

Note: ASR = Age-standardized rate.
Table 2 (continued)

| Region | Country     | population | The proportion in the world population (%) | HDI* | Incidence | Mortality | MIR     |
|--------|-------------|------------|-------------------------------------------|------|-----------|-----------|---------|
|        |             |            |                                           |      | Males     | Females   | Males   | Females | Males | Females |
|        |             |            |                                           |      | Cases(n) ASR (world) | Cases(n) ASR (world) | Cases(n) ASR (world) | Cases(n) ASR (world) |
|        |             |            |                                           |      | Males     | Females   | Males   | Females | Males | Females |
|        |             |            |                                           |      | 4,868     | 288.6     | 2,346   | 131.8   | 4,380  | 1965   | 4,380  | 1965   | 0.68   | 0.51   |
|        |             |            |                                           |      | 6,609     | 230.6     | 3,177   | 99      | 6,045  | 1343   | 6,045  | 1343   | 0.58   | 0.58   |
|        |             |            |                                           |      | 3,448     | 200.4     | 2,223   | 123.1   | 2,702  | 157.1  | 2,702  | 157.1  | 0.78   | 0.54   |
|        |             |            |                                           |      | 1,109     | 210.4     | 772     | 137     | 1,036  | 1343   | 1,036  | 1343   | 0.64   | 0.42   |
|        |             |            |                                           |      | 78,597    | 221.9     | 49,900  | 137     | 76,615 | 1956   | 76,615 | 1956   | 0.88   | 0.56   |
|        |             |            |                                           |      | 40,773    | 230       | 24,545  | 133.7   | 33,599 | 174.1  | 33,599 | 174.1  | 0.76   | 0.51   |
|        |             |            |                                           |      | 12,182    | 261.1     | 6,766   | 136.3   | 10,156 | 67.81  | 10,156 | 67.81  | 0.57   | 0.43   |
|        |             |            |                                           |      | 6,247     | 277.4     | 2,839   | 103.32  | 4,496  | 134.3  | 4,496  | 134.3  | 0.48   | 0.56   |

* United Nations Development Programme. Human Development Report 2020. [http://hdr.undp.org/en/content/download-data](http://hdr.undp.org/en/content/download-data).
Fig 2  Bar chart of region-specific incidence and mortality ASR by sex for cancers in 2020
prostate cancer. These variations might be related to disparities in genetic vulnerability, lifestyle, and local environmental exposures among the different locations. For example, the ASR of alcohol-induced cancer deaths and DALY varied greatly between countries and regions. The highest burden of alcohol-induced cancers was observed in Eastern Europe, and the lowest was observed in North Africa and the Middle East [17]. In countries with a high HDI, the risk of colorectal cancer tends to be relatively high, and incidence and mortality rates have stabilized or declined [18]. The increased incidence of obesity and the increased consumption of dairy products and calcium have previously been associated with an increase in the risk of prostate cancer. In the black population globally, for instance, the incidence of prostate cancer is much higher [19]. Further, the inherent and growing disparities in medical practice and health infrastructure within and between countries also affect the patterns and trends in cancer mortality [20–23]. Two major factors in the decline in prostate cancer deaths are likely to be PSA testing (i.e., more cancers are found at an earlier stage) and better management of patients [24].

Lung cancer remains the most common type of cancer globally, with an estimated 2.1 million new cases and 1.8 million deaths worldwide in 2018 [3]. Lung cancer is the leading cause of cancer incidence and mortality in males among the “B&R” countries as well. Smoking is the leading cause of lung cancer, accounting for 63% of all lung cancer deaths globally and more than 90% of deaths in countries where smoking is common in both sexes [25]. However, the burden of cancer deaths from tobacco products in the “B&R” member countries is heavy, and tobacco control policies have failed to be adequately implemented. In 2018, Turkey, the only member country, implemented five of the six MPOWER measures. Ten countries (Bulgaria, the Czech Republic, Egypt, Nepal, Russia, Saudi Arabia, Slovenia, Thailand, Greece, and Iran) implemented three of the six MPOWER measures, but seven countries have not implemented the MPOWER measures. Furthermore, emerging tobacco products have challenged regulatory approaches to control the public health burden of tobacco-related cancers. Further research should be conducted to determine the risks of emerging tobacco products to accelerate progress in tobacco control while limiting the hazards of existing traditional tobacco products.

The cancer burden among females in the “B&R” countries is considerably high. Breast cancer remains a serious cancer burden in women. According to the latest data in 2020, breast cancer surpassed lung cancer, and for the first time, became the most common cancer in the world (accounting for 11.7% of new cases), ranking the first among the types of cancer worldwide [26]. The rising incidence of breast cancer is associated with the trend of an earlier age at menarche, later age at birth, and parity [27]. Therefore, the incidence of breast cancer can be reduced through regular physical examination screening, postponement or reduction of fertility, reasonable weight control, moderate increases in the amount of exercise, and other control measures. However, nine of the “B&R” countries (Afghanistan, Azerbaijan, Brunei, Cambodia, Nepal, Tajikistan, Uzbekistan, Yemen, and Pakistan) do not yet conduct breast cancer screening. The starting age of the target population for breast cancer screening is mainly between 30 and 50 years of age, and the age of screening in Malaysia, the Maldives, and Bhutan is below 20 years of age. Developing scientific and effective screening methods for breast cancer, improving breast cancer screening programs, and actively carrying out early diagnosis and treatment will remain the key points of breast cancer prevention and treatment in the future.

In addition, cervical cancer carries the highest burden in less developed countries and regions in the “B&R” countries [28], and nearly 100% of cervical cancers are caused by high-risk human papilloma virus (HPV) infection [29]. While cervical cancer is the only common cancer with a clear etiology and can be completely effectively prevented by tertiary prevention [30], and HPV vaccination can protect at least 80% of the target population [31], only 18 of the member countries have HPV vaccination programs in place, of which, vaccination coverage of Bhutan, Brunei, Malaysia, and Turkey is more than 80%, while that in Armenia, the Philippines, Singapore, and Indonesia is less than 5%. Moreover, 12 member states (i.e., Afghan, Egypt, Oman, Saudi Arabia, Tajikistan, Uzbekistan, Yemen, Pakistan, Kyrgyzstan, Kuwait, Iraq, and Iran) do not yet carry out cervical cancer screening. Therefore, the implementation of an HPV vaccination plan and the development of the corresponding screening strategy is the main task of cervical cancer prevention and control in the “B&R” member states.

Infectious agents are the key cause of cancer, particularly in low- and middle-income countries. It was estimated that in 2018, about one-eighth of the 18 million new cancer cases in the world were caused by infection [32]. Hepatitis B virus (HBV) infection, Hepatitis C virus (HCV) infection, liver fluke, and Clonorchis’s sinensis remain the leading infectious factors leading to cancer in low- and middle-income countries [33, 34]. Among other infectious factors, HTLV-1 and large parasites contribute little to the global burden of cancer but are a significant cause of cancer in endemic populations [35]. Moreover, Helicobacter pylori is responsible for a large number of gastrointestinal cancers and deaths [36]. Combination therapy with antibacterial drugs has potential preventive effects. Since 1982, vaccines have been available to
Fig 3 Pie chart of Distribution of major cancer risk factors in the “Belt and Road” geographical location
prevent HBV, and direct-acting antiviral drugs have the potential to cure more than 95% of people infected with HCV [3]. Adequate infection control strategies, including cheap and reliable point-of-care diagnostic tests for specific infectious agents for screening, effective treatments, and therapeutic and preventive vaccines, should all play a broader role in cancer control programs. However, to realize these aspirations, a large amount of international investment is required. Therefore, the “B&R” initiative provides a new platform for international health cooperation.

Ultraviolet radiation directly or indirectly induces DNA damage, leads to mutations, triggers inflammation and immunosuppression, and finally leads to tumor growth. Photocarcinogenesis is a complex, multi-step pathway, which is triggered by the formation of dipyrimidine photoproducts and leads to the formation of mutations (initial stage). Sunburn and inflammation caused by persistent DNA lesions (including dipyrimidine photoproducts and oxidative DNA lesions) play a role in promoting the process of photocarcinogenesis [37]. The dipyrimidine photoproduct triggers ultraviolet-induced immunosuppression, leading to the failure of immune surveillance and the growth and development of cancer cells [38]. The incidence of both melanoma and non-melanoma skin cancer is increasing worldwide, not only in Caucasians [39], but also in Asians, and UV mutations are significantly more common in sun-exposed skin areas than in non-sun-exposed skin areas [40]. The most effective way to reduce the incidence of skin cancer is to avoid unnecessary sun exposure and take personal precautions, such as wearing protective clothing and hats, applying sunscreen, and staying in a cool place, which can significantly reduce the risk of sun damage.

In the wake of the COVID-19 pandemic, awareness of global public health has become clearer, and policy has played a crucial role in promoting global public health. By studying and comparing the incidence, mortality and risk factors of cancer in the “B&R” countries, this study identified different cancer challenges faced by different countries, proposed cancer prevention and control measures applicable to each country, and provided suggestions for health cooperation programs in “B&R” countries. However, the data sources involved in this study are extensive, and the data quality will be uneven. Readers are suggested to quote and extrapolate after reading the analysis methods and data sources of this study in detail.

Conclusion

In summary, the challenges posed by cancer are consistent in the “B&R” member countries. Lung cancer, breast cancer, gastrointestinal cancer, prostate cancer, cervical cancer, thyroid cancer, and uterine cancer were found to be the biggest cancer burdens in the “B&R” countries, and tobacco products, infectious factors, and ultraviolet rays were the main risk factors. Moreover, the corresponding cancer prevention and control policies need to be improved. Therefore, in the context of the health “One Belt One Road” initiative, the collaboration between multiple stakeholders and the sharing of resources will play a positive role in jointly coping with the risks and challenges brought by cancer and promoting the positive development of the health and medical undertaking of all member states and the world at large.

Statement

All methods were carried out in accordance with relevant guidelines and regulations.

Abbreviations

HDI: Human Development Index; CMNNDS: Communicable, Maternal, Neonatal, and Nutritional diseases; NCDs: Non-Communicable Diseases; PBCRs: Population-Based Cancer Registries; ASRs: Age-Standardized Rates; MIR: The mortality/incidence ratio; PAFs: Population Attributable Fractions; ASEAN: The Association of South-East Asian Nations; CIS: The Commonwealth of Independent States; CEE: Central and Eastern Europe; HPV: Human Papilloma Virus; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus.

Supplementary Information

Additional File 1. Supplementary file 1 Comparison of estimated 2020 ASR (world) among East Asia countries, all ages.

Additional File 2. Supplementary file 2 Comparison of estimated 2020 ASR (world) among ASEAN countries, all ages.

Additional File 3. Supplementary file 3 Comparison of estimated 2020 ASR (world) among West Asia countries, all ages.

Additional File 4. Supplementary file 4 Comparison of estimated 2020 ASR (world) among South Asia countries, all ages.

Additional File 5. Supplementary file 5 Comparison of estimated 2020 ASR (world) among Central Asia countries, all ages.

Additional File 6. Supplementary file 6 Comparison of estimated 2020 ASR (world) among CIS countries, all ages.

Additional File 7. Supplementary file 7 Comparison of estimated 2020 ASR (world) among Central and Eastern Europe countries, all ages.

Acknowledgements

We would like to thank the Cancer Surveillance Branch (CSU) and the “B&R” countries for their support of the Global Cancer Observatory and Cancer Country Profiles database.

Authors’ contributions

BW and FH participated in the design, data analysis and drafting of the first manuscript. YH, QW, DW, and YS participated in the data collection and manuscript modification. JW participated in the design of the study and review of the draft manuscript. All authors read and approved the final manuscript.

Funding

No funding resources to be declared.
1. Jointly issued by the National Development and Reform Commission, the References

1 National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (Mailing address: 27 Nanwei Road, Xicheng District, Beijing 100050, China. 2 School of public health, China Medical University, Shenyang, China (Mailing address: 77 Puhe Road, Shendeng New District, Shenyang 110000, China).

Received: 1 July 2021   Accepted: 12 May 2022

Published online: 25 May 2022

11. Sunkara V, Hébert JR. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care[J]. Cancer. 2015;121(10):1563–9. https://doi.org/10.1002/ijc.29228 PMID: 25572676.

12. Teh HS, Woon YL. Burden of cancers attributable to modifiable risk factors in Malaysia[J]. BMC Public Health. 2021;21(1):410. https://doi.org/10.1186/s12889-021-10412-9 PMID:33637056.PMCID:PMC7908668.

13. Jan S, Laba TL, Essue BM, Gheorghe A, Muhunthan J, et al. Action to address the household economic burden of non-communicable diseases[J]. Lancet. 2018;391(10134):2047–58. https://doi.org/10.1016/ S0140-6736(18)30323-4.

14. World Health Organization. Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000–2016[J]. Geneva, Switzerland: World Health Organization. Available from: https://www.who.int/healthinfo/global_burden_disease/en/.

15. Tang K, Li Z, Li W, Chen L. China’s Silk Road and global health[J]. Lancet. 2017;390(10112):2595–601. https://doi.org/10.1016/S0140-6736(17)32998-2 PMID:29231838.PMCID:PMC5715926.

16. Liu P, Guo Y, Qian X, Tang S, Li Z, Chen L. China’s distinctive engagement in global health[J]. Lancet. 2014;384(9945):793–804. https://doi.org/10.1016/S0140-6736(14)60725-X PMID:25176550.PMCID:PMC7159291.

17. World Health Organization. Global status report on alcohol and health 2018[J]. Geneva, Switzerland: World Health Organization. Available from: https://www.who.int/substance_abuse/publications/global_alcohol_report/en/.

18. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jamal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality[J]. Gut. 2017;66(4):683–91. https://doi.org/10.1136/gutjnl-2015-310912 PMID:26818619.

19. Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jamal A, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group[J]. Int J Cancer. 2016;138(6):1388–400. https://doi.org/10.1002/ijc.29894 PMID:26488767.

20. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jamal A. International variation in female breast cancer incidence and mortality rates[J]. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1495–506. https://doi.org/10.1158/1055-9965.PMED.26359465.

21. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jamal A. Global cancer statistics, 2020[J]. CA Cancer J Clin. 2020;70(2):87–106. https://doi.org/10.3322/caac.21578.

22. Torre LA, Siegel RL, Ward EM, Jamal A. International variation in lung cancer mortality rates and trends among women[J]. Cancer Epidemiol Biomarkers Prev. 2014;23(6):1025–36. https://doi.org/10.1158/1055-9965.PMED.24836468.

23. Siegel R, DeSantis C, Jamal A. Colorectal cancer statistics, 2014[J]. CA Cancer J Clin. 2014;64(2):104–17. https://doi.org/10.3322/caac.21220 PMID:24639052.

24. Wong MC, Goggins WB, Wang HHX, Fung FDH, Leung C, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries [J]. Eur Urol. 2015;67:103–8. https://doi.org/10.1016/j.eururo.2015.10.004 PMID:26749482.

25. Wang MC, Goggins WB, Wang HHX, Fung FDH, Leung C, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries [J]. Eur Urol. 2015;67(10):1659–72. https://doi.org/10.1016/j.eururo.2015.10.004 PMID:26749482.

26. World Health Organization. World Health Statistics 2020: Monitoring health for the SDGs, making healthy lives and productive societies for all.[J]. Geneva, Switzerland: World Health Organization. Available from: https://www.who.int/healthinfo/global_burden_disease/en/.

27. World Health Organization. Cancer country profiles 2020. https://www.who.int/cancer/country-profiles/en/ [Accessed on April 8 2021].

28. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jamal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492 PMID:30207593.

29. Weiwei C, Qian X, Tang S, Li Z, Tang K, et al. Global cancer screening: a systematic review and meta-analysis of screening patterns and trends in 36 countries[J]. Eur Urol. 2018;73(3):2729–38. https://doi.org/10.1016/j.eururo.2017.10.004. PMID:28900679.

30. Junlan L. Breast cancer is the most common cancer worldwide for the first time [J]. Chinese Journal of Breast Diseases (Electronic Edition). 2020;4(4):389.

31. Torre LA, Islami F, Siegel RL, Ward EM, Jamal A. Global cancer in women: burden and trends[J]. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–57. https://doi.org/10.1158/1055-9965.PMED.2823433.

32. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis [J]. Lancet Glob Health. 2020;8(2):e191–203. https://doi.org/10.1016/S2214-109X(19)30492-6.

33. Changfa X, Youlin Q, Yong Z, Fanghu Z. WHO’s global strategy of cervical cancer elimination and the challenges and initiatives in China[J]. Natl Med J China. 2020;100(4):3484–8.
30. Lihui W. Facing the challenge of accelerating the elimination of cervical cancer [J]. Chinese Clinical Journal of Obstetrics and Gynaecology. 2021;22(01):1–2.

31. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis [J]. Lancet Glob Health. 2016;4(7):e453–63. https://doi.org/10.1016/S2214-109X(16)30099-7.

32. de Martel C, Georges D, Bray F, Ferlay J, Clifford G. Global burden of cancers attributable to infections in 2018: a worldwide incidence analysis [J]. Lancet Glob Health. 2020;8(2):e180-90. https://doi.org/10.1016/S2214-109X(19)30488-7 PMID:31862245

33. IARC. Biological agents. IARC Monogr Eval Carcinog Risks Hum. 1008:1–441. Available from: http://publications.iarc.fr/119, 2012. PMID:23189750.

34. Bray F, Jamal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study [J]. Lancet Oncol. 2012;13(8):790–801. https://doi.org/10.1016/S1470-2045(12)70211-5 PMID:22658655.

35. Francrchi S, El-Serag HB, Forman D, Newton R, Plummer M. Infectious agents. In: Thun MJ, Linet MS, Cerhan JR, Haiman C, Schottenfeld D, editors. Schottenfeld and Fraumeni cancer epidemiology and prevention. 4th ed. New York (NY), USA: Oxford University Press; 2018. p. 433–60.

36. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 [J]. Lancet 2015; 385(9963):117–71. Doi:https://doi.org/10.1016/S0140-6736(14)61682-2. PMID:25530442.

37. Ellison MJ, Childs JD. Pyrimidine dimers induced in Escherichia coli DNA by ultraviolet radiation present in sunlight. Photochem Photobiol. 1981;34(4):465–9. https://doi.org/10.1111/j.1751-1097.1981.tb09387.x PMID:7031709.

38. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN. Ras gene mutation and amplification in human nonmelanoma skin cancers [J]. Mol Carcinog. 1991;4(3):196–202. https://doi.org/10.1002/mc.2940040306 PMID:2064725.

39. Eismann N, Waldmann A, Geller AC, Weinstock MA, Volkmer B, et al. Nonmelanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol. 2014;134(1):43–50. https://doi.org/10.1038/jid.2013.7. PMID:23877569.

40. Nishigori C. Cellular aspects of photocarcinogenesis. Photochem Photobiol Sci. 2006;5(2):208–14. https://doi.org/10.1039/B507471A PMID:16463307.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.